Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.

Kambe T, Sumiyoshi T, Fujiwara H, Fujimoto T, Takahashi T, Mizuno K, Kubota M, Yamasaki T, Yoshimura K, Tamaki M, Nagumo Y, Kawanishi H, Miyazaki Y, Oshiro H, Kurahashi R, Masuda N, Makino Y, Kobori G, Akamatsu S, Morita S, Kobayashi T, Goto T

Open source

DOI: 10.1007/s10147-026-03177-x
Published: 2026 Aug 25
Container: International journal of clinical oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10147-026-03177-x,
  title = {Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.},
  author = {Kambe T and Sumiyoshi T and Fujiwara H and Fujimoto T and Takahashi T and Mizuno K and Kubota M and Yamasaki T and Yoshimura K and Tamaki M and Nagumo Y and Kawanishi H and Miyazaki Y and Oshiro H and Kurahashi R and Masuda N and Makino Y and Kobori G and Akamatsu S and Morita S and Kobayashi T and Goto T},
  year = {2026},
  journal = {International journal of clinical oncology},
  doi = {10.1007/s10147-026-03177-x},
  url = {https://doi.org/10.1007/s10147-026-03177-x}
}

RIS

TY  - JOUR
TI  - Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.
AU  - Kambe T
AU  - Sumiyoshi T
AU  - Fujiwara H
AU  - Fujimoto T
AU  - Takahashi T
AU  - Mizuno K
AU  - Kubota M
AU  - Yamasaki T
AU  - Yoshimura K
AU  - Tamaki M
AU  - Nagumo Y
AU  - Kawanishi H
AU  - Miyazaki Y
AU  - Oshiro H
AU  - Kurahashi R
AU  - Masuda N
AU  - Makino Y
AU  - Kobori G
AU  - Akamatsu S
AU  - Morita S
AU  - Kobayashi T
AU  - Goto T
PY  - 2026
JO  - International journal of clinical oncology
DO  - 10.1007/s10147-026-03177-x
UR  - https://doi.org/10.1007/s10147-026-03177-x
ER  -

APA

T, K., T, S., H, F., T, F., T, T., K, M., M, K., T, Y., K, Y., M, T., Y, N., H, K., Y, M., H, O., R, K., N, M., Y, M., G, K., S, A., S, M., T, K., & T, G. (2026). Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.. International journal of clinical oncology. https://doi.org/10.1007/s10147-026-03177-x

Source records

pubmed · retrieved 2026-09-26T14:57:22.687Z
europe-pmc · retrieved 2026-09-26T14:57:22.678Z